Andrew MD - Cardiol Therapeutics Chief Development

CRDL Stock  USD 1.36  0.07  4.90%   

Executive

Andrew MD is Chief Development of Cardiol Therapeutics Class
Age 62
Address 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5
Phone289-910-0850
Webhttps://www.cardiolrx.com

Cardiol Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.5415) % which means that it has lost $0.5415 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0844) %, meaning that it created substantial loss on money invested by shareholders. Cardiol Therapeutics' management efficiency ratios could be used to measure how well Cardiol Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.81. The value of Return On Capital Employed is expected to slide to -1.1. At this time, Cardiol Therapeutics' Total Assets are quite stable compared to the past year. Non Current Assets Total is expected to rise to about 610.6 K this year, although the value of Non Currrent Assets Other are projected to rise to (0.95).
Cardiol Therapeutics Class currently holds 174.34 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Cardiol Therapeutics has a current ratio of 6.35, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cardiol Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Found 9 records

EXECUTIVE Age

Holly BellFlora Growth Corp
N/A
Dany VaimanFlora Growth Corp
38
Nicole EsqHCW Biologics
N/A
Uttam PatilABVC Biopharma
38
Stephen DMDPainreform
N/A
Lee FlowersHCW Biologics
78
Rita KeynanPainreform
55
Aaron AtinFlora Growth Corp
39
MD MBAIndaptus Therapeutics
56
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease . Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada. Cardiol Therapeutics is traded on NASDAQ Exchange in the United States. Cardiol Therapeutics Class (CRDL) is traded on NASDAQ Exchange in USA. It is located in 2265 Upper Middle Road East, Oakville, ON, Canada, L6H 0G5 and employs 7 people. Cardiol Therapeutics is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Cardiol Therapeutics Leadership Team

Elected by the shareholders, the Cardiol Therapeutics' board of directors comprises two types of representatives: Cardiol Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cardiol. The board's role is to monitor Cardiol Therapeutics' management team and ensure that shareholders' interests are well served. Cardiol Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cardiol Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Andrew MD, Chief Development
Trevor Burns, Investor Relations
Bernard BSc, Chief Officer
MBA BSCPT, Vice Development
MBA MBA, CEO Pres
David MBA, CEO President
CA CMA, Corp CFO

Cardiol Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cardiol Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Cardiol Therapeutics is a strong investment it is important to analyze Cardiol Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cardiol Therapeutics' future performance. For an informed investment choice regarding Cardiol Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cardiol Therapeutics Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.38)
Return On Assets
(0.54)
Return On Equity
(1.08)
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.